Orphacol: Well established use warrants approval, says European court
This article was originally published in Scrip
Executive Summary
The EU's General Court has annulled a decision by the European Commission to deny approval of Orphacol, a cholic acid-containing orphan drug for rare liver diseases produced by the French firm Laboratoires CTRS. Among other things this means that the product can now receive an EU marketing authorization.